CO COHANCE
Cohance Lifesciences Q2 2025
COCOHANCE

Cohance Lifesciences Q2 FY25 results (Jul–Sep 2024) and concall

Healthcare · Concall AI · Call held 9 Dec 2024

Management summary

  • Suven Pharmaceuticals announced a strategic acquisition of a 56% stake in NJ Bio to become a global leader in the high-growth ADC CDMO market.
  • The deal completes Suven's ADC value chain by adding linker and bioconjugation expertise to its existing payload capabilities.
  • Management is leveraging a strong cash position to fund the $64.4 million investment, targeting significant operating leverage and margin expansion in the mid-term.

Source: Inve concall analysis and management guidance record.

Guidance & targets

Margin

  • EBITDA Margin Margin · CY25 onwards · High confidence 20%+

Capex

  • Primary Equity Infusion for GMP Expansion Capex · FY25-26 · High confidence $15 million

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct
Missing pieces in the ADC value chain (mAb and Fill-Finish) Direct
we strongly believe in leveraging with our strengths... we have not included that as well because there are better strong players who can do these activities outside of us.

Clarifies that Suven is focusing on high-value chemistry (payload/linkers) rather than becoming a fully integrated biological manufacturer immediately.

Asked by Harith Ahamed, Avendus Spark

Revenue split between linkers and conjugation Partial
it is never differentiated between linker, how much of the revenue from linker, how much from a conjugation... This is the bundle project.

Reveals that the business model is largely FTE-based and bundled, making it difficult to track individual component margins but ensuring customer stickiness.

Asked by Girish Bakhru, OrbiMed

Unlock risks & concerns, Q3 FY25 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 3 risks, concerns & management red flags
  • Watchlist triggers for Q3 FY25
  • +2 more guidance targets & verbatim management quotes
  • +1 more analyst Q&A exchange & evasion checks
  • Full section-by-section call narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image